Ela Giladi, Ilya Losin, Ziad Arow, Ranin Hilu, Oded Sabah, Rami Barashi, Alexander Omelchenko, Yoav Arnson, Abid Assali, David Pereg
{"title":"Temporal trends in the treatment with beta-blocker and the effect on outcome of patients with acute myocardial infarction.","authors":"Ela Giladi, Ilya Losin, Ziad Arow, Ranin Hilu, Oded Sabah, Rami Barashi, Alexander Omelchenko, Yoav Arnson, Abid Assali, David Pereg","doi":"10.1097/MCA.0000000000001568","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Early beta-blocker treatment has long been recommended for patients with acute myocardial infarction (AMI), particularly when left ventricular ejection fraction (LVEF) is reduced; however, whether beta-blocker therapy improves outcomes in patients with AMI receiving contemporary treatment remains uncertain. This study aimed to investigate temporal trends in the effect of beta-blocker therapy on outcomes of patients with AMI in a large, nationwide cohort.</p><p><strong>Methods: </strong>Patients with AMI enrolled in the Acute Coronary Syndromes Israeli Survey from 2000 to 2021 were included. They were categorized into three periods: early (2000-2004), mid (2006-2016), and late (2018-2021). Each period group was further divided into two subgroups based on LVEF (>40 and ≤40%) and then stratified by beta-blocker treatment status.</p><p><strong>Results: </strong>The cohort consisted of 11 569 patients. Among patients with LVEF less than 40%, beta-blocker treatment was associated with improved 1-year survival rates in the early (9.1 vs. 20.4%; P < 0.001) and mid (10 vs. 20.6%; P < 0.001) periods only. Among patients with LVEF greater than or equal to 40%, beta-blocker treatment was linked to enhanced 1-year survival in patients enrolled in the early period (3.4 vs. 7.6%; P < 0.001), but not in the mid and late periods.</p><p><strong>Conclusion: </strong>The association between beta-blocker treatment and improved survival in patients with AMI has diminished over recent decades, regardless of LVEF. These findings are likely attributed to the advancements in contemporary medical and revascularization therapy. As such, our results may challenge current recommendations regarding beta-blocker therapy in AMI.</p>","PeriodicalId":10702,"journal":{"name":"Coronary artery disease","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Coronary artery disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MCA.0000000000001568","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Early beta-blocker treatment has long been recommended for patients with acute myocardial infarction (AMI), particularly when left ventricular ejection fraction (LVEF) is reduced; however, whether beta-blocker therapy improves outcomes in patients with AMI receiving contemporary treatment remains uncertain. This study aimed to investigate temporal trends in the effect of beta-blocker therapy on outcomes of patients with AMI in a large, nationwide cohort.
Methods: Patients with AMI enrolled in the Acute Coronary Syndromes Israeli Survey from 2000 to 2021 were included. They were categorized into three periods: early (2000-2004), mid (2006-2016), and late (2018-2021). Each period group was further divided into two subgroups based on LVEF (>40 and ≤40%) and then stratified by beta-blocker treatment status.
Results: The cohort consisted of 11 569 patients. Among patients with LVEF less than 40%, beta-blocker treatment was associated with improved 1-year survival rates in the early (9.1 vs. 20.4%; P < 0.001) and mid (10 vs. 20.6%; P < 0.001) periods only. Among patients with LVEF greater than or equal to 40%, beta-blocker treatment was linked to enhanced 1-year survival in patients enrolled in the early period (3.4 vs. 7.6%; P < 0.001), but not in the mid and late periods.
Conclusion: The association between beta-blocker treatment and improved survival in patients with AMI has diminished over recent decades, regardless of LVEF. These findings are likely attributed to the advancements in contemporary medical and revascularization therapy. As such, our results may challenge current recommendations regarding beta-blocker therapy in AMI.
期刊介绍：
Coronary Artery Disease welcomes reports of original research with a clinical emphasis, including observational studies, clinical trials, translational research, novel imaging, pharmacology and interventional approaches as well as advances in laboratory research that contribute to the understanding of coronary artery disease. Each issue of Coronary Artery Disease is divided into four areas of focus: Original Research articles, Review in Depth articles by leading experts in the field, Editorials and Images in Coronary Artery Disease. The Editorials will comment on selected original research published in each issue of Coronary Artery Disease, as well as highlight controversies in coronary artery disease understanding and management.
Submitted artcles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
